Details of Drug

Drug General Information (ID: D0651)
Drug Name	Ferrous sulfate anhydrous
Drug Type	Small molecule
Drug Synonymous	ferrous salt; FERROUS SULFATE; Iron(II) sulfate; 7720-78-7; Iron sulfate; Iron(2+) sulfate; Iron sulphate; Ferrous sulfate anhydrous; Iron sulfate (1:1); Iron(2+) sulphate; FeSO4; Sulfuric acid, iron(2+) salt (1:1); Iron(II) sulfate (1:1); Sulfuric acid, iron(2+) salt; UNII-2IDP3X9OUD; 2IDP3X9OUD; iron(2+) sulfate (anhydrous); Iron vitriol; Iron(2+) sulfate; Combiron; Odophos; Kesuka; Sal chalybis; Green Salts; Quickfloc (salt); Slow Fe; Ferrosulfat [German]; Ferrosulfat; CCRIS 6796; HSDB 465; SFE 171; EINECS 231-753-5; NSC 57631; NSC 146177; Sulfuric acid, iron(2+) salt (1:?); AI3-51903; 16547-58-3; iron(II)sulphate; Fe(II) sulphate; iron(II) sulphate; EINECS 240-616-9; iron(2+);sulfate; iron (II) sulphate; errous hydrogen sulfide; Ferrous sulfate, 98%; ferrous sulfate (anh.); Fe.SO4; Fe(II)SO4; DSSTox_CID_9688; EC 231-753-5; ferrous sulfate (anhydrous); DSSTox_RID_78808; iron(2+) sulfate (anh.); DSSTox_GSID_29688; Iron(II) sulfate (FeSO4); DTXSID0029688; CHEBI:75832; Ferrous Sulphate Exsiccated (Dried); Tox21_202580; 8644AF; DB13257; NCGC00260129-01; CAS-7720-78-7; FT-0626420; Q214863; 8063-79-4 Click to Show/Hide
Therapeutic Class	Iron Supplement
Structure
Structure	3D Structure		2D Structure
Formula	FeO4S
InChI	InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
InChIKey	BAUYGSIQEAFULO-UHFFFAOYSA-L
Canonical SMILES	[O-]S(=O)(=O)[O-].[Fe+2]
External Link
External Link	Pubchem ID	24393

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM007 Pharmacodynamic antagonistic effects BM003 Complex formation BM005 Altered gastric pH BM009 Altered absorption (Unspecific) BM013 Competitive binding of plasma proteins BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Ferrous sulfate anhydrous
Affected gastrointestinal absorption
	Complex formation					Drug Num: 44
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0181		Bictegravir	C21H18F3N3O5	90311989	Major		Inter Info	[1], [2], [3]
D0515		Dolutegravir	C20H19F2N3O5	54726191	Major		Inter Info	[7], [8]
D0034		Alendronic acid	C4H13NO7P2	2088	Moderate		Inter Info	[9], [10], [11]
D0277		Cefdinir	C14H13N5O5S2	6915944	Moderate		Inter Info	[12], [13]
D0340		Cinoxacin	C12H10N2O5	2762	Moderate		Inter Info	[17], [18], [19]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Moderate		Inter Info	[17], [18], [19]
D0433		Deferiprone	C7H9NO2	2972	Moderate		Inter Info	[20]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Moderate		Inter Info	[17], [18], [19]
D0441		Demeclocycline	C21H21ClN2O8	54680690	Moderate		Inter Info	[21], [22], [23]
D0530		Doxycycline	C22H24N2O8	54671203	Moderate		Inter Info	[21], [22], [23]
D0561		Eltrombopag	C25H22N4O4	135449332	Moderate		Inter Info	[2], [27]
D0573		Enoxacin	C15H17FN4O3	3229	Moderate		Inter Info	[17], [18], [19]
D0575		Entacapone	C14H15N3O5	5281081	Moderate		Inter Info	[28], [29], [30]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[10], [31], [11]
D0144		Baloxavir marboxil	C27H23F2N3O7S	124081896	Moderate		Inter Info	[1], [35]
D0712		Gatifloxacin	C19H22FN3O4	5379	Moderate		Inter Info	[17], [18], [19]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Moderate		Inter Info	[17], [18], [19]
D0740		Grepafloxacin	C19H22FN3O3	72474	Moderate		Inter Info	[17], [18], [19]
D0783		Ibandronate	C9H23NO7P2	60852	Moderate		Inter Info	[9], [10], [11]
D0893		Lanthanum carbonate	C3La2O9	168924	Moderate		Inter Info	[37], [2], [38]
D0918		Levodopa	C9H11NO4	6047	Moderate		Inter Info	[39], [21], [40]
D0919		Levofloxacin	C18H20FN3O4	149096	Moderate		Inter Info	[17], [18], [19]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[41], [42], [8]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[41], [42], [8]
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[41], [42], [8]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Moderate		Inter Info	[17], [18], [19]
D1035		Methyldopa	C10H13NO4	38853	Moderate		Inter Info	[43], [44], [21]
D1070		Minocycline	C23H27N3O7	54675783	Moderate		Inter Info	[21], [22], [23]
D1092		Moxifloxacin	C21H24FN3O4	152946	Moderate		Inter Info	[17], [18], [19]
D1102		Nalidixic acid	C12H12N2O3	4421	Moderate		Inter Info	[45]
D1155		Norfloxacin	C16H18FN3O3	4539	Moderate		Inter Info	[17], [18], [19]
D1165		Ofloxacin	C18H20FN3O4	4583	Moderate		Inter Info	[17], [18], [19]
D1175		Omadacycline	C29H40N4O7	54697325	Moderate		Inter Info	[21], [22], [23]
D1209		Oxytetracycline	C22H24N2O9	54675779	Moderate		Inter Info	[21], [22], [23]
D1245		Penicillamine	C5H11NO2S	5852	Moderate		Inter Info	[46], [47], [48]
D1369		Quinapril	C25H30N2O5	54892	Moderate		Inter Info	[2], [49], [50]
D1412		Risedronic acid	C7H11NO7P2	5245	Moderate		Inter Info	[9], [10], [11]
D1445		Sarecycline	C24H29N3O8	54681908	Moderate		Inter Info	[21], [22], [23]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Moderate		Inter Info	[17], [18], [19]
D1564		Tetracycline	C22H24N2O8	54675776	Moderate		Inter Info	[21], [22], [23]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[41], [42], [8]
D1584		Tiludronic acid	C7H9ClO6P2S	60937	Moderate		Inter Info	[10], [31], [11]
D1635		Triethylenetetramine	C6H18N4	5565	Moderate		Inter Info	[51]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Moderate		Inter Info	[17], [18], [19]
	Altered gastric pH					Drug Num: 7
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0458		Dexlansoprazole	C16H14F3N3O2S	9578005	Moderate		Inter Info	[24], [25], [26]
D0603		Esomeprazole	C17H19N3O3S	9568614	Moderate		Inter Info	[24], [25], [26]
D0892		Lansoprazole	C16H14F3N3O2S	3883	Moderate		Inter Info	[24], [25], [26]
D1179		Omeprazole	C17H19N3O3S	4594	Moderate		Inter Info	[24], [25], [26]
D1222		Pantoprazole	C16H15F2N3O4S	4679	Moderate		Inter Info	[24], [25], [26]
D1373		Rabeprazole	C18H21N3O3S	5029	Moderate		Inter Info	[24], [25], [26]
D0337		Cimetidine	C10H16N6S	2756	Minor		Inter Info	[54], [55], [56]
	Altered absorption (Unspecific)					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0647		Ferric carboxymaltose	C24H44FeO25-	86278165	Moderate		Inter Info	[32], [33], [34]
D0648		Ferric derisomaltose	C18H34FeO16+3	86278348	Moderate		Inter Info	[32], [33], [34]
D0654		Ferumoxytol	Fe3H2O4	14789	Moderate		Inter Info	[32], [33], [34]
D0848		Iron Dextran	FeH2O4S	105075	Moderate		Inter Info	[32], [33], [34]
D0850		Iron sucrose	C12H29Fe5Na2O23	91663255	Moderate		Inter Info	[32], [33], [34]
D1484		Sodium ferric gluconate complex	C6H11FeNaO7+3	23693558	Moderate		Inter Info	[32], [33], [34]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0708		Gallium chloride Ga-67	Cl3Ga	73415785	Moderate		Inter Info	[36]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1776		Dimercaprol	C3H8OS2	3080	Major		Inter Info	[4], [5], [6]
D0313		Chloramphenicol	C11H12Cl2N2O5	5959	Moderate		Inter Info	[14], [15], [16]
D1703		Vitamin E	C29H50O2	14985	Moderate		Inter Info	[52], [53]

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir). Gilead Sciences, Foster City, CA.
4	Desmedt S, Spinewine A, Jadoul M, Henrard S, Wouters D, Dalleur O. Impact of a clinical decision support system for drug dosage in patients with renal failure.?Int J Clin Pharm. 2018;40(5):1225-1233. [PMID: 29785684]
5	Chenoweth MB "Clinical uses of metal-binding drugs." Clin Pharmacol Ther 9 (1968): 365-87. [PMID: 4984845]
6	Product Information. BAL in Oil (dimercaprol). Becton Dickinson, Franklin Lakes, NJ.
7	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
8	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
9	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
10	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
11	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
12	Product Information. Omnicef (cefdinir). Parke-Davis, Morris Plains, NJ.
13	Ueno K, Tanaka K, Tsujimura K, Morishima Y, Iwashige H, Yamazaki K, Nakata I "Impairment of cefdinir absorption by iron ion." Clin Pharmacol Ther 54 (1993): 473-5. [PMID: 8222489]
14	Saidi P, Wallerstein RO, Aggeler PM "Effect of chloramphenicol on erythropoiesis." J Lab Clin Med 57 (1961): 247-56
15	Haile CA "Chloramphenicol toxicity." South Med J 70 (1977): 479-80
16	Scott JL, Finegold SY, Belkin GA, Lawrence JS "A controlled double-blind study of the hematologic toxicity of chloramphenicol." N Engl J Med 272 (1965): 1137-42
17	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
18	Noyes M, Polk RE "Norfloxacin and absorption of magnesium-aluminum." Ann Intern Med 109 (1988): 168-9. [PMID: 3382110]
19	Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J "Effect of Maalox and omeprazole on the bioavailability of trovafloxacin." J Antimicrob Chemother 39 Suppl B (1997): 93-7. [PMID: 9222077]
20	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
21	Campbell NR, Hasinoff BB "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol 31 (1991): 251-5. [PMID: 2054263]
22	Gothoni G, Neuvonen PJ, Mattila M, Hackman R "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand 191 (1972): 409-11. [PMID: 5031537]
23	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
24	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
25	Product Information. Kapidex (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
26	Product Information. Prilosec (omeprazole). Merck &amp Co, Inc, West Point, PA.
27	Product Information. Promacta (eltrombopag). GlaxoSmithKline, Research Triangle Park, NC.
28	Product Information. Comtan (entacapone) Novartis Pharmaceuticals, East Hanover, NJ.
29	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
30	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
31	Product Information. Fosamax (alendronate). Merck &amp Co, Inc, West Point, PA.
32	Product Information. Feraheme (ferumoxytol). Alza Pharmaceuticals, Mountain View, CA.
33	Product Information. INFeD (iron dextran). Schein Pharmaceuticals Inc, Florham Park, NJ.
34	Product Information. Venofer (iron sucrose) American Regent Laboratories Inc, Shirley, NY.
35	Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
36	Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga)). Bristol-Myers Squibb, Princeton, NJ.
37	Canadian Pharmacists Association.
38	Product Information. Seysara (sarecycline). Allergan Inc, Irvine, CA.
39	Campbell NR, Hasinoff B "Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism." Clin Pharmacol Ther 45 (1989): 220-5. [PMID: 2920496]
40	Campbell NR, Rankine D, Goodridge AE, Hasinoff BB, Kara M "Sinemet-ferrous sulphate interaction in patients with Parkinson's disease." Br J Clin Pharmacol 30 (1990): 599-605. [PMID: 2291872]
41	Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC "Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism." Ann Intern Med 117 (1992): 1010-3. [PMID: 1443969]
42	Product Information. Armour thyroid (thyroid desiccated). Forest Pharmaceuticals, St. Louis, MO.
43	Campbell N, Paddock V, Sundaram R "Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate." Clin Pharmacol Ther 43 (1988): 381-6. [PMID: 3356082]
44	Campbell NR, Campbell RR, Hasinoff BB "Ferrous sulfate reduces methyldopa absorption: methyldopa: iron complex formation as a likely mechanism." Clin Invest Med 6 (1990): 329-32. [PMID: 2078911]
45	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.
46	Lyle WH "Penicillamine and iron." Lancet 2 (1976): 420. [PMID: 73880]
47	Netter P, Bannwarth B, Pere P, Nicolas A "Clinical pharmacokinetics of D-penicillamine." Clin Pharmacokinet 13 (1987): 317-33. [PMID: 3319347]
48	Product Information. Cuprimine (penicillamine). Merck &amp Co, Inc, West Point, PA.
49	Multum Information Services, Inc. Expert Review Panel.
50	Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20. [PMID: 10516744]
51	Product Information. Syprine (trientine). Aton Pharma, Lawrenceville, NJ.
52	Graeber JE, Williams ML, Oski FA "The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction." J Pediatr 90 (1977): 282-4
53	Melhorn DK, Gross S "Relationships between iron-dextran and vitamin E in iron deficiency anemia in children." J Lab Clin Med 74 (1969): 789-802
54	Bianchi FM, Cavassini GB, Leo P "Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists." Int J Clin Pharmacol Ther Toxicol 31 (1993): 209-17. [PMID: 8100220]
55	Partlow ES, Campbell NRC, Chan SC, Pap KM, Granberg K, Hasinoff BB "Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion." Clin Pharmacol Ther 59 (1996): 389-93. [PMID: 8612382]
56	Product Information. Tagamet (cimetidine). SmithKline Beecham, Philadelphia, PA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence